Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial
By Dean Seal
Gilead Sciences said an interim analysis of its lenacapavir study showed 100% efficacy in HIV prevention in cisgender women, resulting in a recommendation that the treatment be opened to all trial participants.
The biopharmaceutical company said the phase 3 trial of its twice-yearly injectable HIV-1 capsid inhibitor met key efficacy endpoints of showing superiority to once-daily oral Truvada and background HIV incidence.
The independent data monitoring committee has recommended that Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants.
Gilead said this is the first phase 3 HIV prevention trial to show zero infections.
The company expects results from the lenacapavir program's other phase 3 trial in late 2024 or early 2025. That trial assesses the treatment for pre-exposure prophylaxis, or PrEP, in cisgender men who have sex with men, transgender men, transgender women and gender non-binary individuals who have sex with partners assigned male at birth.
Gilead said the regulatory filing for lenacapavir for PrEP will include the results of both Phase 3 trials.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 20, 2024 09:51 ET (13:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations